Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

stimated," "anticipated," or similar expressions, or by express or implied discussions regarding potential regulatory filings or marketing approvals for RAD001 or regarding potential future revenues from RAD001. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with RAD001 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale for any oncology indication in any market. Nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding RAD001 could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this pre
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  MiMedx Group, Inc.  (NASDAQ: MDXG ... patent-protected regenerative biomaterials and bioimplants processed from human ... initial Investigational New Drug ("IND") application with the ... The IND submission, which was filed yesterday, July ... certain indications of its micronized allografts towards targeted ...
(Date:7/23/2014)... SUNNYVALE, Calif. , July 23, 2014 ... 2014 AUGS/IUGA Scientific Meeting in Washington, D.C. ... a pivotal study of the Pelvalon,s Vaginal Bowel Control ... Director of the Division of Urogynecology and Pelvic Reconstructive ... immediate Past President of the Society for Gynecological Surgeons ...
(Date:7/23/2014)... Indien, July 23, 2014 ... für Arbeiten für Sadara Chemical Company (Sadara) ... Information System innerhalb des integrierten Chemiekomplexes von ... of additional scope im Wert von mehreren ... abgeschlossenen Vertrags dar, dessen Wert sich ebenfalls ...
Breaking Medicine Technology:MiMedx Files Its Initial Investigational New Drug Application 2MiMedx Files Its Initial Investigational New Drug Application 3Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4
... India, and MISSISSAUGA, Ontario, April 1, 2011 Promius ... RDY ), and Valeant Pharmaceuticals International, Inc. ... announced that they have signed a collaboration agreement for ... Pharma will make an upfront payment and pay future ...
... CINCINNATI, April 1, 2011 CarePoint Partners, one of ... in the United States, launched a food drive today ... the less fortunate in the communities where it operates. ... conducted throughout the month of April. CarePoint Partners is ...
Cached Medicine Technology:Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States 2Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States 3Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States 4CarePoint Partners Kicks Off Food Drive to Help Fight Hunger in Twenty-One Local Communities 2
(Date:7/23/2014)... HealthDay Reporter , TUESDAY, July 22, 2014 ... with double the risk of heart attack or stroke in ... among those whose diabetes isn,t well-managed, a new Japanese study ... consumed an average of 5.9 grams of sodium daily had ... consumed, on average, 2.8 grams of sodium daily. In addition, ...
(Date:7/23/2014)... Tenn. July 22, 2014) The voice on the recording was ... brought the news he was infected with the human immunodeficiency virus ... bit and next thing you know I was on the floor ... the message was hopeful when the recording ended less than 10 ... . . . because it is just God setting you ...
(Date:7/23/2014)... 2014 Follow us on ... exclusively developed and manufactured for use in synthetic ... tissues. These materials are biosafe with significantly lower ... market for biocompatible materials is expected to witness ... advancements and growing base of aging population and ...
(Date:7/23/2014)... OH (PRWEB) July 23, 2014 ... AromaMist™ , SpaRoom’s top product and premier diffuser, is ... rubberized feel and an improved motor for maximum quality. ... all-in-one is now available on SpaRoom.com for $60 along ... smart, safe, ultrasonic pulsations to create a long-lasting, tranquil ...
(Date:7/23/2014)... Follow us on LinkedIn ... the marketing mix, with its benefits ranging from ... purchase decision. In a competitive market environment, packaging ... provides ample opportunities for sales growth. Manufacturers are ... such as blister and other high visibility packaging. ...
Breaking Medicine News(10 mins):Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 3Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 3Health News:SpaRoom® Unveils New Sleek Color, Improved AromaMist™ 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4
... Ease Dietary Supplement, a product containing the drug estazolam, which ... for few months. // ,Estazolam belongs to benzodiazepines ... practitioner’s prescription as it may have a number of side ... Hence it is not legal to sell it in Canada. ...
... been on the wish-list of many scientists and sufferers the world ... //Australian scientist, whose perseverance on the capacity of a drug to ... ,Professor Chris Parish , who has been working ... himself and the Australian National University proud, as the drug is ...
... mysterious disease showing symptoms of high fever and bodyache has killed ... ,According to official sources, 12 children died in two or ... the disease commonly referred as 'khasra' by local people. ... the villages. ,"The fear of death had gripped ...
... not withdraw a notification making it mandatory for bidi ... a warning but said its enforcement could be postponed ... parties protested the move saying it would affect the ... Health Minister Anbumani Ramadoss said the government would not ...
... in July. The cause of his death was diagnosed to ... and made African drums, and it is assumed that he ... ,Anthrax is caused by bacterium Bacillus anthracis and commonly occurs ... exposed to infected animals can also be affected. ...
... integral part of the cocktail of drugs consumed by addicts.// ... marijuana, ketamine, heroin and other illicit drugs. ,Ice is used ... have report to work. ,After excessive stimulation by drugs these ... usually smoke ice to get over it. ,Paul Dillon member ...
Cached Medicine News:
... Optical retail software for opticians ... specifically developed for the optical retail ... is the new upgrade replacement for ... a user friendly windows platform. User ...
This product offers patient, product and practice cash management to ease the strain of practice administration....
... First Insight is the leading practice ... for eye care professionals. MaximEyes was ... online servicesrequest VSP authorizations, submit claims ... EMR, scheduling, billing, demographics, recall, insurance, ...
... software for eyecare professionals- Winx ... multi-office practice management system, using ... Winx Pro is a complete ... in effectively managing the administrative, ...
Medicine Products: